PTC Therapeutics Tumbles 60% On Insufficient Marketing Application
February 23, 2016 at 21:52 PM EST
Shares of PTCT fell by 60% after it had announced that the FDA deemed the marketing application as insufficient for review. The company's drug, Translarna, is being used to treat patients with Duchenne muscular dystrophy -- DMD.
